swiTching From etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluatinG the efficacy, tOlerance and safety

Trial Profile

swiTching From etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluatinG the efficacy, tOlerance and safety

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms TANGO
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 25 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top